Thank you for your interest in the COMPPARE study.
COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).”
This study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI) and approved by the University of Florida Institutional Review Board (IRB 201801001; PI: Nancy Mendenhall, MD), will compare the quality of life, side effects, and cure rates for prostate cancer patients treated with proton therapy or photon therapy.
About the study
We will ask 3000 men between the ages of 30-80 across the US who will be treated with either protons or photons to participate in COMPPARE.
Participants will answer brief surveys regarding treatment choice, quality of life, and side effects for at least 3 years.
In addition, proton therapy patients can choose to participate in a randomized trial that will evaluate whether quality of life, side effects, and prostate cancer cure rates differ between patients receiving the standard therapy versus a shorter therapy.
If you have questions about the study, please email the study team at email@example.com.